Acrobiosystems Co.,Ltd. (SHE:301080)

China · Delayed Price · Currency is CNY

90.81

-4.30 (-4.52%)

Oct 22, 2026, 4:00 PM EDT

Market Cap	15.23B +49.2%
Revenue (ttm)	950.35M +29.7%
Net Income	180.12M +19.3%
EPS	1.08 +19.7%
Shares Out	167.68M
PE Ratio	84.33
Forward PE	53.42
Dividend	0.60 (0.66%)
Ex-Dividend Date	Jun 11, 2026

Volume	10,203,690
Open	95.12
Previous Close	95.11
Day's Range	89.50 - 98.28
52-Week Range	35.87 - 141.07
Beta	0.64
Analysts	Buy
Price Target	87.38 (-3.78%)
Earnings Date	Oct 27, 2026

About Acrobiosystems

Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and research institutions. It provides kits, scientific services, and other related products under the Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, and GENPower brands. The company also offers cell therapies, gene therapies, therapeutic antibodies, antibody-drug conjugates, core reagents for infectious disease research, and solutions fo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 926

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301080

Full Company Profile

Financial Performance

In 2025, Acrobiosystems's revenue was 838.12 million, an increase of 29.94% compared to the previous year's 645.02 million. Earnings were 165.57 million, an increase of 33.70%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for 301080 stock is "Buy." The 12-month stock price target is ¥87.38, which is a decrease of -3.78% from the latest price.

Price Target

¥87.38

(-3.78% downside)

Analyst Consensus: Buy

Stock Forecasts